uniQure N.V. has announced progress regarding its investigational gene therapy AMT-130 for Huntington's disease, aligning with the FDA on key components necessary for a Biologics License Application ...
Management reiterated the expectation for top line pivotal data from AMT-130 and initial Fabry data in September, with a planned BLA submission for AMT-130 in the first quarter of 2026. The team ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results